SANES

10.03

-1.26%↓

BBVA

18.59

-1.14%↓

BNP

85.74

-3.99%↓

CABK

10.845

-0.78%↓

INGA

25.045

-1.11%↓

SANES

10.03

-1.26%↓

BBVA

18.59

-1.14%↓

BNP

85.74

-3.99%↓

CABK

10.845

-0.78%↓

INGA

25.045

-1.11%↓

SANES

10.03

-1.26%↓

BBVA

18.59

-1.14%↓

BNP

85.74

-3.99%↓

CABK

10.845

-0.78%↓

INGA

25.045

-1.11%↓

SANES

10.03

-1.26%↓

BBVA

18.59

-1.14%↓

BNP

85.74

-3.99%↓

CABK

10.845

-0.78%↓

INGA

25.045

-1.11%↓

SANES

10.03

-1.26%↓

BBVA

18.59

-1.14%↓

BNP

85.74

-3.99%↓

CABK

10.845

-0.78%↓

INGA

25.045

-1.11%↓

Accueil・Liste d'Actions・Ipsen SA.

Ipsen SA.

Fermé

SecteurFinance

166.4 0.48

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

166.3

Max

166.9

Chiffres clés
By Trading Economics
Revenu	-225M 110M
Ventes	36M 1.9B
P/E Moyenne du Secteur	30.921 57.736
Rendement du dividende	0.84
Marge bénéficiaire	5.899
Employés	5,535
EBITDA	-171M 466M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	-13.25% downside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	0.84% 4.52%
Prochains Résultats	30 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.2B 14B
Ouverture précédente	165.92
Clôture précédente	166.4

Sentiment de l'Actualité

By Acuity

39%

61%

99 / 438 Classement par Finance

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

99.85 / 104 Support & Résistance

Ipsen SA. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 mai 2026, 23:53 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mai 2026, 22:47 UTC

Actions en Tendance

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mai 2026, 22:16 UTC

Acquisitions, Fusions, Rachats

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mai 2026, 22:00 UTC

Principaux Mouvements du Marché

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mai 2026, 18:09 UTC

Principaux Mouvements du Marché

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mai 2026, 23:07 UTC

Acquisitions, Fusions, Rachats

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mai 2026, 23:06 UTC

Acquisitions, Fusions, Rachats

UOB: Share Sale Agreements Entered With Singland Properties

17 mai 2026, 23:05 UTC

Acquisitions, Fusions, Rachats

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire Stake for $389 Million

17 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mai 2026, 16:27 UTC

Acquisitions, Fusions, Rachats

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mai 2026, 15:26 UTC

Acquisitions, Fusions, Rachats

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 22:17 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:59 UTC

Acquisitions, Fusions, Rachats

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mai 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mai 2026, 21:30 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 mai 2026, 20:19 UTC

Actions en Tendance

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mai 2026, 19:41 UTC

Acquisitions, Fusions, Rachats

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mai 2026, 18:35 UTC

Résultats

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparaison

Variation de prix

Ipsen SA. prévision

Objectif de Prix

By TipRanks

-13.25% baisse

Prévisions sur 12 Mois

Moyen 144 EUR -13.25%

Haut 170 EUR

Bas 130 EUR

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

99.85 / 104Support & Résistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

99 / 438Classement par Finance

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.